Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
ONCOLOGY / CLINICAL RESEARCH
Mendelian randomization analysis of 1,400 genetically predicted blood metabolites and ovarian cancer risk
1
North China University of Science and Technology Affiliated Tangshan Maternal and Child Health Care Hospital, China
2
Key Laboratory of Molecular Medicine for Abnormal Development and Related Diseases, Tangshan City, China
Submission date: 2024-09-18
Final revision date: 2025-02-11
Acceptance date: 2025-03-28
Online publication date: 2025-05-18
Corresponding author
Jinghua Wu
North China University of Science and Technology Affiliated Tangshan Maternal and Child Health Care Hospital Key Laboratory of Molecular Medicine for Abnormal Development and Related Diseases Tangshan City, China
North China University of Science and Technology Affiliated Tangshan Maternal and Child Health Care Hospital Key Laboratory of Molecular Medicine for Abnormal Development and Related Diseases Tangshan City, China
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Ovarian cancer is a malignant tumor and a major threat to women’s health. Its development is influenced by diverse factors, among which metabolic dysregulation is increasingly recognized. However, evidence for a causal relationship between metabolic changes and ovarian cancer remains limited. This study aimed to identify potential biomarkers for early screening and a targeted therapeutic strategy.
Material and methods:
A genome-wide association study (GWAS) and a two-sample Mendelian randomization (MR) analysis were applied. Causality was primarily assessed using the random inverse variance weighted (IVW) method. Cross-validation was conducted with MR-Egger, weighted median, and weighted mode approaches. The MR-Egger intercept and Cochran’s Q test were adopted to assess heterogeneity and pleiotropy. Pathway enrichment analysis was performed using MetaboAnalyst 6.0. Our research identified key metabolites as potential biomarkers for early screening and personalized therapy in ovarian cancer. By using MR, we established causal associations between ovarian cancer subtypes and plasma metabolites, offering valuable insights for clinical applications.
Results:
After false discovery rate (FDR) correction, one metabolite, 5-acetylamino-6-amino-3-methyluracil (AAMU), was found to be significantly associated with ovarian cancer risk. Also, significant metabolites were enriched in caffeine metabolism (p < 0.05) as the most significant metabolic pathway in ovarian cancer.
Conclusions:
We integrated genomic and metabolomic analyses to reveal causal associations of metabolites with ovarian cancer and its subtypes. Certain metabolites were identified as prospective biomarkers for ovarian cancer.
Ovarian cancer is a malignant tumor and a major threat to women’s health. Its development is influenced by diverse factors, among which metabolic dysregulation is increasingly recognized. However, evidence for a causal relationship between metabolic changes and ovarian cancer remains limited. This study aimed to identify potential biomarkers for early screening and a targeted therapeutic strategy.
Material and methods:
A genome-wide association study (GWAS) and a two-sample Mendelian randomization (MR) analysis were applied. Causality was primarily assessed using the random inverse variance weighted (IVW) method. Cross-validation was conducted with MR-Egger, weighted median, and weighted mode approaches. The MR-Egger intercept and Cochran’s Q test were adopted to assess heterogeneity and pleiotropy. Pathway enrichment analysis was performed using MetaboAnalyst 6.0. Our research identified key metabolites as potential biomarkers for early screening and personalized therapy in ovarian cancer. By using MR, we established causal associations between ovarian cancer subtypes and plasma metabolites, offering valuable insights for clinical applications.
Results:
After false discovery rate (FDR) correction, one metabolite, 5-acetylamino-6-amino-3-methyluracil (AAMU), was found to be significantly associated with ovarian cancer risk. Also, significant metabolites were enriched in caffeine metabolism (p < 0.05) as the most significant metabolic pathway in ovarian cancer.
Conclusions:
We integrated genomic and metabolomic analyses to reveal causal associations of metabolites with ovarian cancer and its subtypes. Certain metabolites were identified as prospective biomarkers for ovarian cancer.
REFERENCES (57)
1.
Chen X, Chen S, Li Y, et al. SMURF1-mediated ubiquitination of ARHGAP26 promotes ovarian cancer cell invasion and migration. Exp Mol Med 2019; 51: 1-12.
2.
Huang J, Chan WC, Ngai CH, et al. Worldwide burden, risk factors, and temporal trends of ovarian cancer: a global study. Cancers 2022; 14: 2230.
3.
Wang W, Cho U, Yoo A, et al. Wnt/b-catenin inhibition by CWP232291 as a novel therapeutic strategy in ovarian cancer. Front Oncol 2022; 12: 852260.
4.
Li P, Lin B, Chen Z, et al. Biodegradable hollow mesoporous organosilica nanotheranostics (HMONs) as a versatile platform for multimodal imaging and phototherapeutic-triggered endolysosomal disruption in ovarian cancer. Drug Deliv 2022; 29: 161-73.
5.
Nayak RC, Hegde S, Althoff MJ, et al. The signaling axis atypical protein kinase C l/i-Satb2 mediates leukemic transformation of B-cell progenitors. Nat Commun 2019; 10: 46.
6.
Jeon Y, Yoo JE, Rhee H, et al. YAP inactivation in estrogen receptor alpha-positive hepatocellular carcinoma with less aggressive behavior. Exp Mol Med 2021; 53: 1055-67.
7.
Yan Z, Wang Q, Zhao S, et al. OSov: an interactive web server to evaluate prognostic biomarkers for ovarian cancer. Biology 2021; 11: 23.
8.
Wang Z, Wang S, Qin J, et al. Splicing factor BUD31 promotes ovarian cancer progression through sustaining the expression of anti-apoptotic BCL2L12. Nat Commun 2022; 13: 6246.
9.
Müller C, Zidek LM, Ackermann T, et al. Reduced expression of C/EBPb-LIP extends health and lifespan in mice. eLife 2018; 7: e34985.
10.
Zhang Z, Song M, Lv Z, Guo M, Li C. Gut microbiota mediates skin ulceration syndrome outbreak by readjusting lipid metabolism in Apostichopus japonicus. Int J Mol Sci 2022; 23: 13583.
11.
Nuzzo D, Amato A, Picone P, et al. A natural dietary supplement with a combination of nutrients prevents neurodegeneration induced by a high fat diet in mice. Nutrients 2018; 10: 1130.
12.
Gray ALH, Antevska A, Link BA, et al. a-CGRP disrupts amylin fibrillization and regulates insulin secretion: implications on diabetes and migraine. Chem Sci 2021; 12: 5853-64.
13.
Zhou M, Guan W, Walker LD, et al. Rapid mass spectrometric metabolic profiling of blood sera detects ovarian cancer with high accuracy. Cancer Epidemiol Biomarkers Prev 2010; 19: 2262-71.
14.
Giron LB, Peluso MJ, Ding J, et al. Markers of fungal translocation are elevated during post-acute sequelae of SARS-CoV-2 and induce NF-kB signaling. JCI Insight 2022; 7: e160989.
15.
Davaatseren M, Hwang JT, Park JH, Kim MS, Wang S, Sung MJ. Poly-g-glutamic acid attenuates angiogenesis and inflammation in experimental colitis. Mediators Inflamm 2013; 2013: 982383.
16.
Hernandez C, Molusky M, Li Y, Li S, Lin JD. Regulation of hepatic ApoC3 expression by PGC-1b mediates hypolipidemic effect of nicotinic acid. Cell Metab 2010; 12: 411-9.
17.
Takata Y, Shrubsole MJ, Li H, et al. Plasma folate concentrations and colorectal cancer risk: a case-control study nested within the Shanghai Men’s Health Study. Int J Cancer 2014; 135: 2191-8.
18.
Hagenbeek FA, van Dongen J, Pool R, et al. Heritability of urinary amines, organic acids, and steroid hormones in children. Metabolites 2022; 12: 474.
19.
Chen Y, Lu T, Pettersson-Kymmer U, et al. Genomic atlas of the plasma metabolome prioritizes metabolites implicated in human diseases. Nat Genet 2023; 55: 44-53.
20.
Burgess S, Davey Smith G, Davies NM, et al. Guidelines for performing Mendelian randomization investigations: update for summer 2023. Wellcome Open Res 2019; 4: 186.
21.
Skrivankova VW, Richmond RC, Woolf BAR, et al. Strengthening the reporting of observational studies in epidemiology using mendelian randomization: the STROBE-MR statement. JAMA 2021; 326: 1614-21.
22.
Phelan CM, Kuchenbaecker KB, Tyrer JP, et al. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet 2017; 49: 680-91.
23.
Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Archiv 2012; 460: 237-49.
24.
Reay WR, Geaghan MP, Cairns MJ. The genetic architecture of pneumonia susceptibility implicates mucin biology and a relationship with psychiatric illness. Nat Commun 2022; 13: 3756.
25.
Pierce BL, Ahsan H, Vanderweele TJ. Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. Int J Epidemiol 2011; 40: 740-52.
26.
Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan N, Thompson J. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat Med 2017; 36: 1783-802.
27.
Larsson SC, Burgess S, Michaëlsson K. Association of genetic variants related to serum calcium levels with coronary artery disease and myocardial infarction. JAMA 2017; 318: 371-80.
28.
Greco MF, Minelli C, Sheehan NA, Thompson JR. Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome. Stat Med 2015; 34: 2926-40.
29.
Wootton RE, Lawn RB, Millard LAC, et al. Evaluation of the causal effects between subjective wellbeing and cardiometabolic health: mendelian randomisation study. BMJ 2018; 362: k3788.
30.
Hartwig FP, Davies NM, Hemani G, Davey Smith G. Two-sample Mendelian randomization: avoiding the downsides of a powerful, widely applicable but potentially fallible technique. Int J Epidemiol 2016; 45: 1717-26.
31.
Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol 2016; 40: 304-14.
32.
Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol 2015; 44: 512-25.
33.
Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG. Sensitivity analyses for robust causal inference from Mendelian randomization analyses with multiple genetic variants. Epidemiology 2017; 28: 30-42.
34.
Brown DG, Rao S, Weir TL, et al. Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metabol 2016; 4: 11.
35.
Liu D, Tian QY, Zhang J, et al. Association between 25 hydroxyvitamin d concentrations and the risk of COVID-19: a mendelian randomization study. Biomed Environ Sci 2021; 34: 750-4.
36.
Bae SC, Lee YH. Causal association between rheumatoid arthritis and a decreased risk of Alzheimer’s disease: a Mendelian randomization study. Z Rheumatol 2019; 78: 359-64.
37.
Bowden J, Spiller W, Del Greco MF, et al. Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the radial plot and radial regression. Int J Epidemiol 2018; 47: 1264-78.
38.
Pang Z, Lu Y, Zhou G, et al. MetaboAnalyst 6.0: towards a unified platform for metabolomics data processing, analysis and interpretation. Nucleic Acids Res 2024; 52: W398-406.
39.
Qi X, Wang J, Che X, et al. The potential value of cuprotosis (copper-induced cell death) in the therapy of clear cell renal cell carcinoma. Am J Cancer Res 2022; 12: 3947-66.
40.
Purwaha P, Gu F, Piyarathna DWB, et al. Unbiased lipidomic profiling of triple-negative breast cancer tissues reveals the association of sphingomyelin levels with patient disease-free survival. Metabolites 2018; 8: 41.
41.
Chen Y, Zhou Y, Han F, et al. A novel miR-1291-ERRa-CPT1C axis modulates tumor cell proliferation, metabolism and tumorigenesis. Theranostics 2020; 10: 7193-210.
42.
Cascone T, McKenzie JA, Mbofung RM, et al. Increased tumor glycolysis characterizes immune resistance to adoptive T cell therapy. Cell Metab 2018; 27: 977-87.e4.
43.
Fu D, Geschwind JF, Karthikeyan S, et al. Metabolic perturbation sensitizes human breast cancer to NK cell-mediated cytotoxicity by increasing the expression of MHC class I chain-related A/B. Oncoimmunology 2015; 4: e991228.
44.
Huber V, Camisaschi C, Berzi A, et al. Cancer acidity: an ultimate frontier of tumor immune escape and a novel target of immunomodulation. Semin Cancer Biol 2017; 43: 74-89.
45.
Casero RA Jr, Murray Stewart T, Pegg AE. Polyamine metabolism and cancer: treatments, challenges and opportunities. Nat Rev Cancer 2018; 18: 681-95.
46.
Holbert CE, Foley JR, Murray Stewart T, Casero RA Jr. Expanded potential of the polyamine analogue SBP-101 (diethyl dihydroxyhomospermine) as a modulator of polyamine metabolism and cancer therapeutic. Int J Mol Sci 2022; 23: 6798.
47.
Luengo A, Gui DY, Vander Heiden MG. Targeting metabolism for cancer therapy. Cell Chem Biol 2017; 24: 1161-80.
48.
Reaves ML, Young BD, Hosios AM, Xu YF, Rabinowitz JD. Pyrimidine homeostasis is accomplished by directed overflow metabolism. Nature 2013; 500: 237-41.
49.
Wang W, Cui J, Ma H, Lu W, Huang J. Targeting pyrimidine metabolism in the era of precision cancer medicine. Front Oncol 2021; 11: 684961.
50.
Chen X, Li A, Sun BF, et al. 5-methylcytosine promotes pathogenesis of bladder cancer through stabilizing mRNAs. Nat Cell Biol 2019; 21: 978-90.
51.
Long Y, Sanchez-Espiridion B, Lin M, et al. Global and targeted serum metabolic profiling of colorectal cancer progression. Cancer 2017; 123: 4066-74.
52.
McEligot AJ, Poynor V, Sharma R, Panangadan A. Logistic LASSO regression for dietary intakes and breast cancer. Nutrients 2020; 12: 2652.
53.
Gregg JR, Kim J, Logothetis C, et al. Coffee intake, caffeine metabolism genotype, and survival among men with prostate cancer. Eur Urol Oncol 2023; 6: 282-8.
54.
Grundy A, Sandhu S, Arseneau J, et al. Lifetime caffeine intake and the risk of epithelial ovarian cancer. Cancer Epidemiol 2022; 76: 102058.
55.
Kotsopoulos J, Vitonis AF, Terry KL, et al. Coffee intake, variants in genes involved in caffeine metabolism, and the risk of epithelial ovarian cancer. Cancer Causes Control 2009; 20: 335-44.
56.
Lee WJ, Zhu BT. Inhibition of DNA methylation by caffeic acid and chlorogenic acid, two common catechol-containing coffee polyphenols. Carcinogenesis 2006; 27: 269-77.
57.
Kurzawa-Akanbi M, Tammireddy S, Fabrik I, et al. Altered ceramide metabolism is a feature in the extracellular vesicle-mediated spread of alpha-synuclein in Lewy body disorders. Acta Nneuropathol 2021; 142: 961-84.
Share
RELATED ARTICLE
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
